Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

Preliminary results from the AACR 2025 Annual Meeting reveal encouraging clinical responses to the investigational oral agent ...

A new combination therapy has been found to give better results for patients with a certain type of colorectal cancer that no ...

Croatian confectionery producer Kras [ZSE:<a href=" target="_blank">KRAS] said on Wednesday it has proposed to shareholders ...

KRAS G12C inhibitors mark a breakthrough in oncology, but resistance is driving the need for smarter preclinical models and ...

“This trial is the first time we’ve ever seen this kind of benefit in treating non-small cell lung cancers caused by KRAS-G12D,” Dr. Arbour says. “What we saw in these patients is dramatically ...

HonorHealth Research Institute's new downtown Phoenix laboratory has produced its first study, centered on a promising new ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped responding to chemotherapy, according to a Phase 3 clinical trial by ...

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...